FONDAZIONE ITALIANA SCLEROSI MULTIPLA - FISM ETS

Their core work

FISM is the research foundation of the Italian Multiple Sclerosis Association, one of the largest MS patient organizations in Europe. They fund and conduct research on multiple sclerosis and related neurological conditions, with a strong focus on patient engagement, treatment adherence, and translating clinical evidence into better care models. Their H2020 work bridges patient advocacy with data-driven health research, applying machine learning and IoT to monitor brain diseases and improve shared decision-making between patients and clinicians.

What they specialise in

How they've shifted over time

FISM's H2020 journey started in 2018 with MULTI-ACT, a coordination project focused on research governance — how to measure research impact and genuinely involve patients in the research process. By 2021, their focus shifted sharply toward applied digital health: machine learning for brain disease diagnosis (ALAMEDA) and behavioural modelling for treatment adherence (BEAMER). The trajectory is clear — from policy and frameworks toward data-driven, technology-enabled patient care.

FISM is moving from soft research governance toward hard digital health tools — expect future work combining patient behavioural data with AI-driven clinical decision support.

How they like to work

FISM plays a dual role: they can coordinate projects (MULTI-ACT) but more often join as domain experts bringing patient-side perspective and MS-specific knowledge. With 54 unique partners across 18 countries from just 3 projects, they operate in large, diverse consortia — typical of health research where clinical, technical, and patient advocacy expertise must converge. Their value in a consortium is as the patient organization that grounds technical work in real clinical needs.

Despite only 3 projects, FISM has built a broad network of 54 partners across 18 countries, reflecting the large consortium sizes typical of EU health research. Their reach spans most of Europe with no obvious geographic concentration beyond Italy.

What sets them apart

FISM occupies a rare position at the intersection of patient advocacy, clinical research, and digital health. Unlike purely academic groups or tech companies, they bring the patient perspective backed by real disease-specific expertise — particularly valuable for projects that need to demonstrate patient engagement and real-world health outcomes. For consortium builders, FISM offers both credibility with the MS patient community and hands-on research capacity in behavioural health and digital tools.

Highlights from their portfolio

• MULTI-ACT
  FISM's only coordinated project (EUR 577K), developing a research impact framework — shows their ambition to shape how patient-centered research is designed and evaluated.
• ALAMEDA
  Marks FISM's entry into AI-driven health tech, combining machine learning and IoT for early diagnosis of MS, Parkinson's, and stroke — a significant technical leap from their governance roots.